Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can mindfulness ease psychosis in teens and young adults?

NCT ID NCT07645443

Symptom relief Sponsor: Stephanie Mehl Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 10, 2026 · Updated 5 times

Summary

This study tests whether a 4-week mindfulness group therapy program, added to usual care, can reduce symptoms in 252 young people (ages 16-35) hospitalized for early psychosis. Participants are randomly assigned to either the mindfulness program plus standard treatment or standard treatment alone. The main goal is to see if mindfulness helps lower overall psychiatric symptoms after 4 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mindfulness-based group therapy
What this could lead to
If it works, this could offer a new, drug-free way to help young people manage psychosis symptoms during hospitalization.
What could go wrong
This is an early-stage trial with no phase, so results are uncertain. The therapy is added to standard care, so any benefit may be small or hard to separate from usual treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 252 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 to 35 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 16 to 35 years * Clinical diagnosis of early psychosis, defined as first psychotic episode within the last 5 years as assessed with the Structural Clinical Interview for DSM-5 Research Version (SCID-5-RV) * DSM-5 schizophrenia spectrum or other psychotic disorder confirmed with SCID-5-RV (DSM-5: 297.1, 298.8, 295.4, 295.9, 295.7, 298.8, 298.9) Currently receiving inpatient/day clinic treatment with a planned stay of at least 4 weeks * Interested in and willing to participate in FEEL-GOOD and/or TAU. Exclusion Criteria: * Insufficient German language abilities * Acute suicidality or acute threat to others

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brief psychotic disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

delusional disorder early-onset schizophrenia Emotional Regulation paranoid schizophrenia psychiatric disorder psychotic disorder Psychotic Disorders schizophrenia schizophreniform disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brief psychotic disorder Delusional disorder Early onset psychosis First episode psychosis First psychotic episode within the last 5 years Other psychotic disorder not due to A substance or known physiological condition Psychosis Psychosis nos Randomized controlled trial (RCT) Schizophrenia / schizoaffective disorder Schizophrenia spectrum disorders (SSD) Schizophreniform disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Charité-Universitätsmedizin Berlin (CCM), Department of Psychiatry and Psychotherapy, , Charitéplatz 1, D-10117 Berlin, Germany

    RECRUITING

    Berlin, State of Berlin, 10117, Germany

  • Ludwig-Maximilians Universität Munich, Department of Psychiatry and Psychotherapy, Nussbaumstr. 7, 80336 Munich

    RECRUITING

    München, Bavaria, 80336, Germany

  • Marburg University, Department of Psychiatry and Psychotherapy, Rudolf-Bultmann-Str. 8, 35039 Marburg, Germany

    RECRUITING

    Marburg, Hesse, 35039, Germany

  • University of Augsburg, Department of Psychiatry and Psychotherapy, Geschwister-Schoenert-Str. 1, 86156 Augsburg

    RECRUITING

    Augsburg, Bavaria, 86156, Germany

  • University of Cologne, Department of Psychiatry and Psychotherapy, Kerpener Str. 62, 50937 Cologne

    RECRUITING

    Cologne, North Rhine-Westphalia, 50937, Germany

  • University of Hamburg, Universitätsklinikum Hamburg-Eppendorf Hamburg, Department of Psychiatry and Psychotherapy

    RECRUITING

    Hamburg, Free and Hanseatic City of Hamburg, 20246, Germany

  • University of Mannheim, Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, J5, 68169 Mannheim

    RECRUITING

    Mannheim, Baden-Wurttemberg, 68159, Germany

  • Vivantes Klinikum am Urban, Hospital for Psychiatry, Psychotherapy und Psychosomatics, Dieffenbachstr. 1, 10967 Berlin

    RECRUITING

    Berlin, State of Berlin, 10967, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.